BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is up 16.67% in pre-market trading to $6.16 after the company’s opioid treatment received FDA approval. Belbuca, the newly-approved treatment, has been approved for patients experiencing chronic and severe pain to the point that they require around-the-clock opioid treatment. The drug should become commercially available in the first quarter of 2016. Since the drug was produced in partnership with Endo Pharmaceuticals, the FDA approval triggered a $50 million milestone payment from Endo to BDSI. As of this writing, 3 analysts on TipRanks have weighed in on BDSI in the last 3 months, all with bullish ratings. The average 12-month price target between these 3 analysts is $16.67, marking a 215% potential increase from where shares last closed.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) fell 4.61% in pre-market trading down to $110.80 as the company hosted a conference call to clear the air after last week’s chaos. To recap, Citron Research accused the pharmaceutical company of being the next Enron, insinuating fraud in its business model. Accusations say that Valeant is using Philidor, a specialty pharmaceutical company, for fake invoices that convey Valeant as being its only customer. Valenat’s management, including its Chief Compliance Officer, is walking shareholders through its partnership with Philidor though shares have continued to fall throughout the phone call. Analysts have been eager to weigh in on the company since the news media frenzy erupted with several new ratings in the last week. According to TipRanks, out of the 15 analysts who have rated the stock in the last 3 months, 9 are bullish on the company, 5 are neutral, and 1 is bearish. The average 12-month price target on the stock is $242.79, marking a 109% potential increase from where the stock last closed.
Ctrip.com International, Ltd. (ADR) (NASDAQ:CTRP) soared 18.78% in pre-market trading to $88.32 while Baidu Inc (ADR) (NASDAQ:BIDU) rose 7.99% to $170.20 after Quanar Cayman Islands Ltd announced that the two companies will be forming a partnership. According to the deal, Baidu and Ctrip will each own shares of the other. The two companies will benefit from industry consolidation as Baidu is a web-services company and CTrip is a leading Chinese travel company. All 9 analysts polled by TipRanks in the last 3 months are bullish on Ctrip. The average 12-month price target on the stock is $94.43, marking a 27% potential upside from where shares last closed. On the other hand, 6 analysts on TipRanks are bullish on Baidu while 4 are staying on the sidelines. The average 12-month price target for the stock is $196.75, marking a 24% potential upside from current levels.